美女露出‰100奶头网站,国产一级 片内射毛片,久久久久国产精品无码免费看,毛片毛片毛片毛片毛片,久久亚洲精品无码Va白人极品

中文
中文
為了病患而驅(qū)動(dòng)的創(chuàng)新
Patient-first cell therapy innovation
 

Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy
  • 0


On the cover: 
The transdifferentiation paths of erythroid precursor cells (EPCs) under the influence of tumor is delineated from Palantir algorithm‐based single-cell transcriptomic trajectory analysis (Long et al., 674–693), and embedded into artwork inspired by Wassily Kandinsky's “Composition 8.” As acquired “organs,” tumors exert a self-beneficial influence on the immune system by hijacking of erythropoiesis for myelopoiesis. Besides exacerbating anemia, CD45+ EPCs transdifferentiation generates myeloid cells that robustly curtail anti‐tumor immunity. Clinically, the abundance of these converted cells predicts immune tolerance in many human tumor types and resistance to immune checkpoint inhibitor treatment. Design and painting by Yijie Hou. Conceptual visualization by Qi-Jing Li and Bo Zhu.

https://www.cell.com/cancer-cell/current#closeFullCover

 

Copyright ? 2019 天科雅生物醫(yī)藥科技有限公司

粵公網(wǎng)安備 44011502000528號(hào)

粵ICP備20056630號(hào) Powered by vancheer
關(guān)于天科雅
研究與發(fā)展
產(chǎn)品及臨床
新聞與媒體
招賢納士

Copyright ? 2019 天科雅生物醫(yī)藥科技有限公司

粵公網(wǎng)安備 44011502000528號(hào)

粵ICP備20056630號(hào) Powered by vancheer